There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
NCT05154513
Recruiting
IMPAACT 2028 is an observational prospective study to characterize a cohort of early treated children who may participate in future research related to HIV remission or cure. Up to approximately 250 participants will be in the study for approximately seven years. No intervention is provided in the study.
Gender:
All
Ages:
All
Trial Updated:
03/11/2024
Locations: David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California
Conditions: HIV Infection
Register for Updates
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
NCT04374305
Recruiting
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2-SWN to receive n... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
03/11/2024
Locations: UCLA Medical Center, Los Angeles, California
Conditions: Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
All
Ages:
All
Trial Updated:
03/11/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
Recruiting
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: University of Southern California, Los Angeles, California +1 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
NCT05859724
Recruiting
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2024
Locations: UCLA Department of Medicine, Los Angeles, California
Conditions: Atopic Dermatitis
Register for Updates
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
NCT04558164
Recruiting
The purpose of this study is to see if stimulation of the brain can improve memory. The investigators will use a device called transcranial magnetic stimulation that can stimulate and activate a specific part of the brain that is important for memory. The study will enroll MCI subjects and subjects with subjective memory complaints who will be randomly assigned to receive active or sham brain stimulation. 'Blinded' or 'sham-controlled' means that the subject will not know whether the treatment t... Read More
Gender:
All
Ages:
Between 55 years and 100 years
Trial Updated:
03/08/2024
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Cognitive Dysfunction, Memory Disorders in Old Age
Register for Updates
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
NCT05394103
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Los Angeles General Medical Center, Los Angeles, California +1 locations
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
NCT04544007
Recruiting
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
Gender:
All
Ages:
22 years and below
Trial Updated:
03/08/2024
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: NF1, Low-grade Glioma
Register for Updates
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
NCT05438420
Recruiting
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
Register for Updates
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
NCT05467176
Recruiting
This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Tower Urology, Los Angeles, California
Conditions: Prostate Cancer
Register for Updates
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
NCT05743036
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Metastatic Colorectal Cancer
Register for Updates